Wang et al. studied the relationship between marmesin and esophageal cancer by targeting the PI3K/AKT pathway, they found that Marmesin exerted anticancer activity in esophageal cancer cells by inhibiting PI3K/AKT pathway, and speculated that PIK3CA was a key oncogene related to the activation of the PI3K/AKT pathway [79]. Here, AKT1 is linked to esophageal cancer.